United States: Fresenius Kabi Announces FDA Approval Of TYENNE, A Tocilizumab Biosimilar Referencing ACTEMRA - Goodwin Procter LLP

Mondaq

19 Mar 2024 0 shares 2 views

United States: Fresenius Kabi Announces FDA Approval Of TYENNE, A Tocilizumab Biosimilar Referencing ACTEMRA - Goodwin Procter LLP

Mondaq

Published 19 Mar 2024

On March 7, Fresenius Kabi announced that the FDA has approved its tocilizumab biosimilar, TYENNE (tocilizumab-aazg) for inflammatory and immune diseases indications including rheumatoid arthritis...

Full Article

United States: Fresenius Kabi's Actemra® Biosimilar Tyenne® (Tocilizumab-aazg) Approved In The U.S. - Venable LLP

On March 5, 2024, the FDA approved Fresenius Kabi's Tyenne® (tocilizumab-aazg) as a biosimilar of Chugai, Genentech and Hoffman-La..

Mondaq 20 Mar 2024

United States: Teva And Alvotech's Adalimumab Biosimilar Receives Interchangeable Status At FDA - Goodwin Procter LLP

On February 23rd, 2024, Alvotech and Teva announced FDA's approval of SIMLANDI (adalimumab-ryvk), the first high-concentration and..

Mondaq 12 Mar 2024

United States: Fresenius Kabi Announces FDA Approval Of TYENNE, A Tocilizumab Biosimilar Referencing ACTEMRA - Goodwin Procter LLP

United States: Fresenius Kabi Announces FDA Approval Of TYENNE, A Tocilizumab Biosimilar Referencing ACTEMRA - Goodwin Procter LLP

You might like

Related news coverage

United States: Fresenius Kabi's Actemra® Biosimilar Tyenne® (Tocilizumab-aazg) Approved In The U.S. - Venable LLP

United States: Teva And Alvotech's Adalimumab Biosimilar Receives Interchangeable Status At FDA - Goodwin Procter LLP

Advertisement